Menu
Search
|

Menu

Close
X

Adamas Pharmaceuticals Inc ADMS.OQ (NASDAQ Stock Exchange Global Market)

10.82 USD
-0.02 (-0.18%)
As of Nov 16
chart
Previous Close 10.84
Open 10.84
Volume 180,015
3m Avg Volume 180,262
Today’s High 10.92
Today’s Low 10.46
52 Week High 43.98
52 Week Low 10.46
Shares Outstanding (mil) 22.51
Market Capitalization (mil) 520.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.92 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
21
FY17
1
FY16
1
FY15
2
EPS (USD)
FY18
-3.825
FY17
-3.956
FY16
-2.766
FY15
-2.862
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
2,939.55
5.69
Price to Book (MRQ)
vs sector
5.00
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
32.50
15.71
LT Debt to Equity (MRQ)
vs sector
32.50
11.53
Return on Investment (TTM)
vs sector
-44.88
15.05
Return on Equity (TTM)
vs sector
-51.05
16.62

EXECUTIVE LEADERSHIP

Gregory Went
Chairman of the Board, Chief Executive Officer, Co-Founder, Since 2000
Salary: $517,500.00
Bonus: $384,244.00
Alfred Merriweather
Chief Financial Officer, Since 2017
Salary: $203,077.00
Bonus: $110,071.00
Christopher Prentiss
Chief Accounting Officer, Since 2017
Salary: --
Bonus: --
Jennifer Rhodes
Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer, Since 2016
Salary: $246,311.00
Bonus: $82,215.00
Rajiv Patni
Chief Medical Officer, Since 2015
Salary: $381,380.00
Bonus: $169,333.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1900 Powell St Ste 1000
EMERYVILLE   CA   94608-1839

Phone: +1510.4503554

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

SPONSORED STORIES